AMRI ups hydroxychloroquine sulfate API production

By The Science Advisory Board staff writers

May 1, 2020 -- AMRI Global will boost production of hydroxychloroquine sulfate active pharmaceutical ingredients (API) due to its potential effectiveness in treating COVID-19 symptoms in patients.

AMRI's active type II drug master file for hydroxychloroquine sulfate, which was issued an emergency use authorization by the U.S. Food and Drug Administration to treat some hospitalized patients with COVID-19, is available to support increased need.

The company remains committed to working with drug product producers, government agencies, and associated health authorities globally to ensure access to this API as demand increases.

If you like this content, please share it with a colleague!

Related Reading

COVID-19: A double-edged sword for the pharma industry
The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the...

New antiviral drug could work against many viruses, including SARS-CoV-2
An antiviral drug called EIDD-2801 that's in preclinical testing has potential to be developed into the silver bullet that medical professionals seek...

Samsung Biologics, Vir partner on SARS-CoV-2 program
Samsung Biologics announced it will manufacture Vir Biotechnology's SARS-CoV-2 monoclonal antibody program for a potential COVID-19 treatment.

Controversy hits Gilead over orphan status for COVID-19 drug
Gilead Sciences has rescinded its request for orphan drug status for an experimental drug for treating COVID-19 just two days after getting approval from...

Frontera supercomputer aids COVID-19 drug development
Scientists are urgently working to build the first complete all-atom model of the SARS-CoV-2 coronavirus envelope, estimated to contain over 200 million...